Georgia Life Sciences Designates Augusta as Newest BioReady® Community

Georgia Life Sciences Designates Augusta as Newest BioReady® Community

AUGUSTA, GA-May 15, 2025 –  The City of Augusta has been designated a BioReady Gold Community by the state’s leading life sciences membership organization, Georgia Life Sciences. To receive this distinction, communities must meet certain criteria related to zoning practices and infrastructure capacity. 

 

“We are proud to recognize the City of Augusta as our latest BioReady community. A hub for life sciences, boasting Augusta University's Health Sciences Campus, including the Medical College of Georgia, and companies like Manus, Augusta is known as the ‘City of Medicine,’” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Through this program, we champion communities that have made a commitment to expanding access to resources and infrastructure, boosting commercialization.”

 

The BioReady rating system rates communities in three tiers from Bronze to Silver to Gold. Through these BioReady ratings, Georgia Life Sciences allows local municipalities to better showcase biotech-zoned science parks, streamline permitting, build a robust infrastructure, and identify biotech-friendly sites more effectively, making them a desirable choice for real estate developers and biotechnology companies seeking destinations to locate.

 

For more information about this recognition, visit the BioReady Communities website at https://www.galifesciences.org/resources/bioready-communities.

May 13, 2026
Georgia Life Sciences thanks Dr. Marty Makary for his service as Commissioner of the U.S. Food and Drug Administration during a period of significant change across the nation’s health and regulatory agencies.
May 12, 2026
Georgia Life Sciences is pleased to announce Tim Opler as a featured keynote speaker at the 2026 Georgia Life Sciences Summit, taking place August 25-26 at the Sandy Springs Performing Arts Center in Atlanta. A leading voice in biotech investment banking, Tim Opler serves as Managing Director in Stifel’s Global Healthcare Group, where he advises innovative life sciences companies on financing, growth strategy, and market positioning across the healthcare landscape. Tim brings deep insight into the evolving biotech investment environment, emerging industry trends, and the factors shaping the future of life sciences innovation and commercialization. Join us for this timely discussion with one of the industry’s most respected financial leaders as we explore the opportunities and challenges defining the next era of life sciences growth . 
May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology
MORE POSTS